Sort   by:  
 Page size 
Genomicsena-DATASET-GNE-22-02-2018-22:43:32:906-1098 - samples
RNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. RNA was sequenced using a capture based approach (exome capture, RNA access).
EGAD00001003977 | EGA
Genomicsena-DATASET-GNE-27-07-2018-23:28:18:139-1120 - samples
Tumor DNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. Normal DNA was extracted from matched PBMCs. Whole exome sequencing was performed. This is a subset of patients for which RNA sequencing is also pro...
EGAD00001004218 | EGA
GenomicsTGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA ...
EGAS00001002556 | EGA
GenomicsData access committee handling data access requests for biomarker data from the clinical trial IMvigor210.
Data Access Committee EGAC00001000945
EGAC00001000945 | EGA
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.

Background

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in ...
S-EPMC8693692 | biostudies-literature
Sort   by:  
 Page size